Introduction
============

Diabetic nephropathy is associated with mortality and morbidity in patients with diabetes mellitus.[@B1] The most common method of detecting the early signs of diabetic nephropathy is the measurement of microalbuminuria.[@B2] However, pathological abnormalities have been reported to occur before the onset of microalbuminuria.[@B3] In chronic cases of diabetic nephropathy, renal function correlates better with the degree of tubulointerstitial injury rather than with glomerular lesions, suggesting that researchers should look for tubular biomarkers in order to identify patients with diabetic nephropathy.[@B4] There has been an increasing interest in identifying other biomarkers that might give a sensitive and rapid means of detecting the progression of diabetic nephropathy. In this aspect, biomarkers that reflect tubular damage have been suggested by many investigators.[@B5] ^,^ [@B6]

Zinc-alpha-2-glycoprotein (ZAG) is a protein of interest because of its ability to play many important functions in the human body, including fertilization and lipid mobilization. Its structural organization and folding characteristics are similar to the MHC class I antigen-presenting molecule; hence, ZAG may have a role in the immune response. The function of ZAG under physiologic and cancerous conditions remains mysterious; however, it is considered a tumor biomarker for various carcinomas. There are several unrelated functions attributed to ZAG, such as RNase activity, regulation of melanin production, hindering of tumor proliferation, and transport of nephritic by-products[@B7].

ZAG is present in a variety of epithelia and is secreted into many body fluids.[@B8] It was found that urine ZAG increased specifically in patients with diabetes and it may be used as a biomarker for specific and accurate analysis of diabetic nephropathy.[@B9] Immunohistochemical analyses have shown that ZAG is expressed mainly in the tubules of the human kidney.[@B10]

We hypothesized that the urine and serum concentrations of ZAG might increase earlier than microalbuminuria in diabetic nephropathy. This study aimed to determine the role of ZAG in the early diagnosis of diabetic nephropathy by estimating the concentrations of urine and serum ZAG in patients with type 2 diabetes mellitus (T2DM), according to their levels of albuminuria.

Subjects and methods
====================

Study design:
-------------

This was a case-control study carried out in the Internal Medicine and Clinical Pathology departments, Faculty of Medicine, Zagazig University, from December 2017 to August 2018.

Participants and groups:
------------------------

A total of 88 persons were included after their written informed consent and classified into 4 main groups. Control group (group I) were normal healthy volunteers (n = 22). The three T2DM patient groups were divided according to urinary albumin/creatinine ratio (UACR) into: normo-albuminuria group (group II) (UACR \< 30 mg/g, n = 22, further subdivided according to eGFR into 2 subgroups: normal eGFR subgroup and increased eGFR subgroup \> 120mL/min/1.73m^2^), DN group with microalbuminuria (group III, UACR from 30 to 300 mg/g, n = 22) and DN with macroalbuminuria (group IV, UACR \> 300 mg/g, n = 22). All groups were matched for age, sex, and body mass index.

Exclusion criteria:
-------------------

Patients with hepatic diseases, heart failure, thyroid disorders, autoimmune diseases, inflammatory conditions and sepsis, malignancy, renal impairment of known origin, urinary tract infections, past history of rapidly progressive renal failure, any type of glomerulonephritis, and patient with polycystic kidney were excluded from the study.

Physical examination and measurements:
--------------------------------------

All subjects in the study were subjected to A) assessment of medical history and thorough clinical examination according to patients\' records; B) routine investigations according to the methods applied in the clinical pathology laboratories of Zagazig University hospitals including urine analysis, complete blood count, fasting and random blood glucose levels, HbA1c, liver function tests, serum creatinine, urea, uric acid, lipid profile and calculation of eGFR. The modification of diet in renal disease (MDRD) equation was used for eGFR (mL/min/1.73 m^2^): 175 x (Scr)^-1.154^ x (Age)^-0.203^ x (0.742 if female)[@B11]. The urine albumin was divided by 100 to convert mg/dL to g/L and then the urine albumin value was divided by the urine creatinine value to albumin creatinine ratio (UACR) (mg/g) (urine albumin (mg/L) x100/ urine creatinine (mg/dL)). UACR was reported as (mg albumin/g creatinine)[@B12]. C) Specific investigations included measurement of urinary and serum ZAG by human ZAGp1 (Zinc-alpha-2-glycoprotein) ELISA Kit (Spanbiotec, Guandong, China). D) Other investigations included electrocardiogram and abdominal ultrasound.

Statistical analysis
--------------------

The collected data were computerized and statistically analyzed using SPSS program (Statistical Package for Social Science) version 18.0. Qualitative data were presented as frequencies and relative percentages. Chi-square test was used to calculate difference between qualitative variables. Quantitative data were presented as mean ± SD (standard deviation). Independent T-test was used to compare differences between quantitative variables in two groups with normally distributed data. ANOVA F-test test was used to compare differences between quantitative variables in more than two groups with normally distributed data. Kruskal Wallis test was used to compare differences between quantitative variables in more than two groups with non-normally distributed data. Pearson correlation coefficient was used to calculate correlation between quantitative variables. Receiver operating characteristic (ROC) curve analysis was used to identify optimal cut-off values of Vnn-1 with maximum sensitivity and specificity for prediction of the disease. Accuracy was measured by the area under the ROC curve. *p*-values \> 0.05 indicated non-significant results, \< 0.05 indicated significant results and \< 0.01 indicated highly significant results.

Results
=======

Our results showed that there was no significant difference among groups regarding age, weight, and sex while there was a significant difference regarding the duration of diabetes mellitus ([Table 1](#t1){ref-type="table"}). We found significant differences among groups regarding fasting blood glucose (FBG), random blood glucose (RBG), HbA1C, serum creatinine, eGFR, urinary albumin/creatinine ratio, serum albumin, and total plasma proteins ([Table 2](#t2){ref-type="table"}). There were significant differences among groups regarding both urinary and serum ZAG and estimated GFR ([Table 3](#t3){ref-type="table"}). [Table 3](#t3){ref-type="table"} shows the number and percentage of subjects according to eGFR in all groups. There was a significant positive correlation between both urinary and serum ZAG and duration of DM, UACR, and with each other, while a negative significant correlation was found between both urinary and serum ZAG and serum albumin, total plasma proteins, and eGFR ([Table 4](#t4){ref-type="table"}). There was a significant increase in serum and urinary ZAG in cases with eGFR \> 120 mL/min when compared to cases with normal eGFR (90 to 120 mL/min) in the normoalbuminuric group II ([Table 5](#t5){ref-type="table"}). The accuracy of urinary ZAG was 95.5%, and that of serum ZAG was 90.9%; considering both of them, the accuracy was 95.5% ([Table 6](#t6){ref-type="table"} & [Figure 1](#f1){ref-type="fig"}).

###### Comparison of different variables among the study groups

  ------------------------------------------------------------------------------------------------------------------------------------------
  Variable                        Group I\        Group II\      Group III\     Group IV\      F        *p*                           
                                  (n = 22)        (n = 22)       (n = 22)       (n = 22)                                              
  ------------------------------- --------------- -------------- -------------- -------------- -------- ---------- ---- ------ ------ ------
  Age (years) Mean ± SD           51 ± 6.62       51 ± 6.91      51 ± 6.29      51 ± 5.76      0.01     0.99                          

  Weight (Kg): Mean ± SD          80.36 ± 7.65    79.59 ± 9.42   81.18 ± 9.12   80.95 ± 6.59   0.16     0.92                          

  DM Duration (years) Mean ± SD   \-\-\-\-\-\--   4.59 ± 0.95    7.91 ± 0.97    12.68 ± 2.82   111.62   \< 0.001                      

  Variable                        No              \%             No             \%             No       \%         No   \%     χ2     *p*

  Sex                                                                                                                                  

  Male                            13              59.1           11             50             12       54.5       13   59.1   0.51   0.92

  Female                          9               40.9           11             50             10       45.5       9    40.9          
  ------------------------------------------------------------------------------------------------------------------------------------------

*p*-value \< 0.05 is significant. DM: diabetes mellitus, SD: standard deviation

###### Comparison of different variables among the study groups

  ------------------------------------------------------------------------------------------------------------------------
  Variable                          Group I\        Group II\        Group III\       Group IV\        F        *p*
                                    (n = 22)        (n = 22)         (n = 22)         (n = 22)                  
  --------------------------------- --------------- ---------------- ---------------- ---------------- -------- ----------
  FBG: (mg/dl)\                     79.89 ± 13.51   131.36 ± 56.65   141.82 ± 73.37   150.89 ± 94.83   6.354    0.001
  Mean ± SD                                                                                                     

  RBG: (mg/dl)\                     92.07 ± 8.23    160.93 ± 93.86   194.64 ± 98.85   180.14 ±66.26    10.020   \< 0.001
  Mean ± SD                                                                                                     

  HbA1c: (%)\                       5.19 ± 0.335    7.77 ± 1.74      8.64 ± 1.49      8.49 ± 1.18      18.428   \< 0.001
  Mean ± SD                                                                                                     

  S. uric acid: (mg/dl) Mean ± SD   5.28 ± 1.09     4.63 ± 1.03      4.71 ± 1.07      4.97 ± 1.17      1.59     0.2

  S. Cr: (mg/dL)\                   0.882 ± 0.136   1.13 ± 0.533     3.48 ± 1.16      5.45 ± 2.91      45.749   \< 0.001
  Mean ± SD                                                                                                     

  eGFR: (mL/min)\                   108.73 ± 7.11   124.09±11.23     98.86 ± 3.85     82.36 ± 4.87     125.43   \< 0.001
  Mean ± SD                                                                                                     

  UACR: (mg/g)\                     20.4 ± 5.11     20.72 ± 5.37     77.74 ± 28.93    383.55 ± 61.59   569.05   \< 0.001
  Mean ± SD                                                                                                     

  Albumin: (g/dL)\                  4.53 ± 0.66     4.15 ± 0.54      4.19 ± 0.58      3.31 ± 0.08      22.06    \< 0.001
  Mean ± SD                                                                                                     

  T. protein: (g/dL)\               7.26 ± 0.55     7.12 ± 0.52      7.21 ± 0.54      6.39 ± 0.09      16.85    \< 0.001
  Mean ± SD                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------

FBG: fasting blood glucose, RBG: random blood glucose, HbA1C: glcosylated hemoglobin, S. Cr: serum creatinine, eGFR: estimated glomerular filtration rate, UACR: urinary albumin creatinine ratio, *p*-value \< 0.05 is significant.

###### Comparison of eGFR, and urinary and serum ZAG among the studied groups

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Variable                        Group I\       Group II\      Group III\     Group IV\      F        *p*                            
                                  (n = 22)       (n = 22)       (n = 22)       (n = 22)                                               
  ------------------------------- -------------- -------------- -------------- -------------- -------- ---------- ---- ------ ------- ----------
  Urinary ZAG: (mg/g) Mean ± SD   26.91 ± 2.41   36.86 ± 3.76   46.09 ± 2.31   56.73 ± 2.62   444.93   \< 0.001                       

  Serum ZAG: (mg/l) Mean ± SD     20.27 ± 1.52   24.55 ± 1.68   32.23 ± 2.11   40.82 ± 1.89   545.43   \< 0.001                       

  eGFR:                           No             \%             No             \%             No       \%         No   \%     χ2      *p*

  \< 90                           0              0              0              0              0        0          19   86.4            

  90 - 120                        22             100            8              36.4           22       100        3    13.6   119.7   \< 0.001

  \> 120                          0              0              14             63.6           0        0          0    0               
  ----------------------------------------------------------------------------------------------------------------------------------------------

ZAG: zinc-alpha-2-glycoprotein, eGFR: estimated glomerular filtration rate, *p*-value \< 0.05 is significant.

###### Correlation between both urinary and serum ZAG and different variables among the three patients groups

  -------------------------------------------------------------------------------
  Variable                 Urinary ZAG\   Serum ZAG\                  
                           (n = 66)       (n = 66)                    
  ------------------------ -------------- ------------- ------------- -----------
  Age (years)              0.06           0.63          0.002         0.98

  Weight                   0.13           0.31          0.07          0.56

  Duration of DM (years)   0.88           \< 0.001      0.86          \< 0.001

  Albumin (g/dL)           -0.51          \< 0.001      -0.52         \< 0.001

  Total protein (g/dL)     -0.49          \< 0.001      -0.47         \< 0.001

  FBS: (mg/dL)             0.04           0.74          0.03          0.84

  RBG: (mg/dL)             -0.02          0.9           -0.02         0.99

  HbA1c: (%)               -0.08          0.51          -0.02         0.86

  eGFR: (mL/min)           -0.78          \< 0.001      -0.87         \< 0.001

  Uric acid: (mg/dL)       0.16           0.2           0.12          0.34

  Creatinine:(mg/dL)       0.15           0.23          0.08          0.46

  UACR: (mg/g)             0.86           \< 0.001      0.89          \< 0.001

  Urinary ZAG: (mg/g)      \-\-\-\--      \-\-\-\-\--   0.93          \< 0.001

  Serum ZAG: (mg/L)        0.93           \< 0.001      \-\-\-\-\--   \-\-\-\--
  -------------------------------------------------------------------------------

DM: diabetes mellitus, FBG: fasting blood glucose, RBG: random blood glucose, HbA1C: glycosylated hemoglobin, S.Cr: serum creatinine, eGFR: estimated glomerular filtration rate, UACR: urinary albumin creatinine ratio, ZAG: zinc-alpha-2-glycoprotein, *p*-value \< 0.05 is significant.

###### Relation between urinary and serum ZAG and eGFR in Group II and Group IV

  ------------------------------- --------------- -------------- ------ ----------
  Variable                        Group II        t              *p*    

  GFR 90 - 120\                   GFR \> 120\                           
  (n = 8)                         (n = 14)                              

  Urinary ZAG: (mg/g) Mean ± SD   32.63 ± 2.77    39.29 ± 1.14   7.99   \< 0.001

  Serum ZAG: (mg/L) Mean ± SD     24.38 ± 1.51    26.44 ± 1.82   2.71   0.01

  Variable                        Group IV        t              *p*    

  GFR \< 90\                      GFR 90 - 120\                         
  (n = 19)                        (n = 3)                               

  Urinary ZAG: (mg/g) Mean ± SD   56.63 ± 2.69    57.33 ± 2.52   0.42   0.78

  Serum ZAG: (mg/L) Mean ± SD     40.37 ± 1.61    41.67 ± 0.58   1.36   0.19
  ------------------------------- --------------- -------------- ------ ----------

ZAG: zinc alpha 2 glycoprotein, *p*-value \< 0.05 is significant

###### Validity of Urinary and serum ZAG in prediction of albuminuria

  Variable      Cutoff   AUC    Sens.   Spec.   +PV    -PV    Accuracy   *p*-value
  ------------- -------- ------ ------- ------- ------ ------ ---------- -----------
  Urinary ZAG   ≥ 28.5   0.99   98.5    86.4    95.6   95     95.5       \< 0.001
  Serum ZAG     ≥ 22.5   0.99   97      72.7    91.4   88.9   90.9       \< 0.001
  Both          \--      0.99   97      90.9    96.9   90.9   95.5       \< 0.001

ZAG: zinc alpha 2 glycoprotein, NPV: negative predictive value, PPV: positive predictive value, *p*-value \< 0.05 is significant.

Figure 1Roc curve for Validity of urinary and serum ZAG in prediction of albuminuria.

Discussion
==========

Microalbuminuria is considered the earliest clinical manifestation of DN.[@B3] DN affects all cellular components in the glomeruli and renal tubular interstitium.[@B4] As glomerular damage usually results in proteinuria, much research has been undertaken on glomerular damage in patients with T2DM.[@B13] However, some patients with diabetes can have a decrease in eGFR and may progress to end-stage renal disease without having any significant albuminuria.[@B14] Some patients with microalbuminuria have advanced renal pathological changes for which therapy is less effective than one might usually expect for those with early stage disease.[@B13] ^,^ [@B14] The correlation between albuminuria and eGFR has been found to be weak and urinary albumin lacks both sensitivity and specificity to detect early stages of DN.[@B14]

Several tubular biomarkers that can predict renal damage in patients with early diabetic nephropathy have been investigated, such as neutrophil-gelatinase associated lipocalin, kidney injury molecule 1, and liver fatty acid binding protein.[@B7]

Our study aimed to investigate the role of ZAG in early diagnosis of DN by estimating the concentrations of urine and serum ZAG in patients with T2DM, according to their levels of albuminuria.

Because our groups were matched regarding age, body weight and sex, the effect of these factors on the results of urinary and serum ZAG in our study were excluded. A significant difference was found regarding the duration of T2DM which is in agreement with other studies that found a significant difference between normo- and microalbuminuric groups regarding duration of diabetes mellitus.[@B15] ^-^ [@B17]

The results for FBG, RBG, HbA1C, serum creatinine, eGFR, urinary albumin/creatinine ratio, serum albumin and total plasma proteins were in agreement with another study, which documented a significant difference between both diabetic groups regarding the previous parameters.[@B18] Another study reported that progression of diabetic nephropathy was accompanied by declining GFR and increasing urinary albumin excretion.[@B19] We found that serum albumin in Group IV was statistically decreased compared to the other groups, which is in line with another study that found that serum albumin was significantly lower in the macroalbuminuric group of DN patients[@B20].

A significant difference between control and normo-albuminuric groups was found as for GFR by MDRD. These results were demonstrated by other studies[@B21] ^-^ [@B23]. This can be explained by the pathogenesis of diabetic nephropathy, as there is hyperfiltration in stage 1 due to an imbalance in afferent and efferent arteriolar resistance, resulting in increased glomerular hydrostatic pressure and hyperfiltration. Activation of the renin-angiotensin system (RAS) increases angiotensin II levels, leading to efferent arteriolar vasoconstriction and production of proinflammatory and profibrotic molecules through multiple mechanisms.[@B24]

Regarding GFR, other studies also found significant difference between control and normo-albuminuric patients (high eGFR subgroup), being lower in the normoalbuminuric group.[@B25] ^,^ [@B26] On the other hand, our study found significant differences regarding GFR by MDRD between control and micro-albuminuric groups, which is in line with another study that reported that albuminuria is the strongest risk factor for fast annual eGFR decline.[@B27]

In our study, a significance differences was found among studied groups in both urinary and serum ZAG levels. The increase of urinary ZAG in diabetic groups is the result of the proximal tubules in the kidneys being particularly susceptible to diabetes-associated injury, as they are subjected to prolonged exposure to various metabolic and hemodynamic disturbances.[@B28] In prolonged cases of DN, renal function correlates better with the degree of tubulointerstitial injury than the degree of glomerular lesions.[@B29]

As ZAG is mainly expressed in the proximal convoluted and straight tubules,[@B10] the changes in ZAG urine concentrations observed in our study might be indicative of the tubular damage that is present in earlier stages of diabetic nephropathy, preceding those that result in microalbuminuria.

Another study reported that the concentration of ZAG in urine was higher than that in serum, especially in patients with T2DM, which suggests that the increased urine concentrations of ZAG were mainly due to increased ZAG secretion by tubular epithelial cells.[@B30] Other studies demonstrated that urine ZAG levels were progressively increased in diabetic patients with normo-, micro-, and macroalbuminuria indicating that it is positively related with diabetes nephropathy progression.[@B31]

Moreover, other studies indicated that the appearance of ZAG in albumin-negative urine samples preceded the appearance of albumin in T2DM patients from South Asia, suggesting that ZAG may be an early novel urinary biomarker useful for the screening of non-albuminuric DN.[@B32]

In our study there were significant positive correlations between both urinary and serum ZAG and duration of DM, UACR, and with each other. Negative significant correlation was found between both urinary and serum ZAG and albumin, total plasma proteins and eGFR, in contrast with another study that reported an inverse relationship between ZAG levels and plasma proteins.[@B33]

We found that urine concentrations of ZAG were significantly increased in patients with T2DM with higher eGFR compared with T2DM patients with normal eGFR.

The serum ZAG concentration was positively correlated with eGFR but not with glucose levels, body weight and serum creatinine, which is in agreement with another study.[@B30]

Conclusion
==========

The strong positive association between urinary ZAG concentrations and UACR, and the earlier appearance of urine ZAG compared with albuminuria, suggest that ZAG might be a useful biomarker for the early diagnosis of DN in patients with T2DM.

Large-scale prospective studies are needed to comprehensively understand the potential pathophysiological role of ZAG in DN and to determine the cause-effect relationship between urine and serum concentrations of ZAG and DN.

The authors thank all participants of the study, and colleagues and staff of the department.

**Erratum:** In the article "Zinc alpha 2 glycoprotein as an early biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus", with DOI code <http://dx.doi.org/10.1590/2175-8239-jbn-2018-0200>, published in the Brazilian Journal of Nephrology, ePub ahead of print on March 18, 2019, the name and information of the first author was missing:

In the original version the information was:

Khaled A Elhefnawy^1^ <http://orcid.org/0000-0002-2024-5449>

George Emad^1^

Mabrouk Ismail^1^

Maher Borai^2^

^1^Faculty of Medicine, Internal Medicine Department, Zagazig University, Egypt.

^2^Faculty of Medicine, Clinical Pathology Department, Zagazig University, Egypt.

The correct information is:

Mohamed Elsheikh^1^

Khaled A Elhefnawy^1^ <http://orcid.org/0000-0002-2024-5449>

George Emad^1^

Mabrouk Ismail^1^

Maher Borai^2^

^1^Faculty of Medicine, Internal Medicine Department, Zagazig University, Egypt.

^2^Faculty of Medicine, Clinical Pathology Department, Zagazig University, Egypt.
